Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
What Are Angiogenesis Inhibitors and How Do They Work?
A chemical that interferes with the signals to form new blood vessels is referred to as an angiogenesis inhibitor.
Sometimes called antiangiogenic therapy, this experimental treatment may prevent the growth of cancer by blocking the formation of new blood vessels. In some animal case studies, angiogenesis inhibitors have caused cancer to shrink and resolve completely.
In humans, angiogenesis inhibitors are only used in clinical trials at this time. These drugs are still considered investigational. Research studies are now underway to help scientists learn whether the approach will apply to human cancers. Patients with cancers of the breast, prostate, pancreas, lung, stomach, ovary, cervix, and others are being studied. If the research studies demonstrate that angiogenesis inhibitors are both safe and effective for cancer treatment in humans, these drugs will need approval by the US Food and Drug Administration (FDA) to become available for widespread use.
The Stanford Medicine Online Second Opinion program offers you easy access to our world-class doctors. It’s all done remotely and you don’t have to visit our hospital or one of our clinics for this service. You don’t even need to leave home!